ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Agilent To Acquire Diagnostics Firm

by Michael McCoy
May 21, 2012 | APPEARED IN VOLUME 90, ISSUE 21

Agilent Technologies has agreed to acquire Dako, a Danish cancer diagnostics company, for $2.2 billion. Agilent CEO Bill Sullivan says the acquisition, the largest in the company’s history, is part of an effort to increase sales and improve its presence in life sciences. Dako, now owned by the European private equity firm EQT Partners, provides antibodies, reagents, scientific instruments, and software primarily to customers in pathology labs. Dako also collaborates with drug companies to develop diagnostics that identify patients most likely to benefit from a specific therapy. Its 2010 sales were about $340 million. Scientific instrument makers have identified clinical diagnostics as a growth market. Last year, Agilent rival Thermo Fisher Scientific spent $3.5 billion to acquire Phadia, a Swedish maker of allergy and autoimmunity diagnostic tests.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment